Ropivacaine inhibits pressure-induced lung endothelial hyperpermeability in models of acute hypertension

Milan Patel, Andreia Z. Chignalia, Ayman Isbatan, Nikhil Bommakanti, Randal O. Dull

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims: Increases in hydrostatic pressure results in endothelial hyperpermeability via eNOS-dependent pathways. Ropivacaine is known to inhibit eNOS activation and to attenuate lung injury. Herein, we sought to determine if ropivacaine regulates pressure-induced lung endothelial hyperpermeability. Main methods: The effects of ropivacaine on lung permeability were assessed in two models of acute hypertension (AH): the isolated perfused lung preparation where acute increases in left atrial pressure model the hemodynamic changes of severe hypertension, and an animal model of AH induced by norepinephrine. In the IPL model, whole lung filtration coefficient (K f ) was used as the index of lung permeability; pulmonary artery pressure (P pa ), pulmonary capillary pressures (P pc ), and zonal characteristics (ZC) were measured to assess the effects of ropivacaine on hemodynamics and their relationship to K f2 /K f1 . In vivo, ropivacaine effects were investigated on indices of pulmonary edema (changes in P a O 2 lung wet-to-dry ratio), changes in plasma volume and nitric oxide (NO) production. Key findings: Ropivacaine provided robust protection from pressure-dependent barrier failure; it inhibited pressure-induced increases in K f without affecting P pa , P pc or ZC. In vivo, ropivacaine prevented pressure-induced lung edema and associated hyperpermeability as evidence by maintaining P a O 2 , lung wet-to-dry ratio and plasma volume in levels similar to sham rats. Ropivacaine inhibited pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs. Significance: Collectively these data show that ropivacaine inhibits pressure-induced lung endothelial hyperpermeability and suggest that ropivacaine may be a clinically useful agent to prevent endothelial hyperpermeability when pulmonary pressure is acutely increased.

Original languageEnglish (US)
Pages (from-to)22-28
Number of pages7
JournalLife Sciences
Volume222
DOIs
StatePublished - Apr 1 2019

Fingerprint

Hypertension
Pressure
Lung
Pulmonary Edema
Capillarity
Hemodynamics
Plasma Volume
Nitric Oxide
ropivacaine
Permeability
Plasmas
Hydrostatic pressure
Hydrostatic Pressure
Atrial Pressure
Lung Injury
Tyrosine
Rats
Norepinephrine
Animals
Pulmonary Artery

Keywords

  • Local anesthetics
  • Mechanotransduction
  • Pulmonary edema and filtration coefficient
  • Vascular barrier

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ropivacaine inhibits pressure-induced lung endothelial hyperpermeability in models of acute hypertension. / Patel, Milan; Chignalia, Andreia Z.; Isbatan, Ayman; Bommakanti, Nikhil; Dull, Randal O.

In: Life Sciences, Vol. 222, 01.04.2019, p. 22-28.

Research output: Contribution to journalArticle

Patel, Milan ; Chignalia, Andreia Z. ; Isbatan, Ayman ; Bommakanti, Nikhil ; Dull, Randal O. / Ropivacaine inhibits pressure-induced lung endothelial hyperpermeability in models of acute hypertension. In: Life Sciences. 2019 ; Vol. 222. pp. 22-28.
@article{dc5ec3e91dc247e685a4beb835dc8f49,
title = "Ropivacaine inhibits pressure-induced lung endothelial hyperpermeability in models of acute hypertension",
abstract = "Aims: Increases in hydrostatic pressure results in endothelial hyperpermeability via eNOS-dependent pathways. Ropivacaine is known to inhibit eNOS activation and to attenuate lung injury. Herein, we sought to determine if ropivacaine regulates pressure-induced lung endothelial hyperpermeability. Main methods: The effects of ropivacaine on lung permeability were assessed in two models of acute hypertension (AH): the isolated perfused lung preparation where acute increases in left atrial pressure model the hemodynamic changes of severe hypertension, and an animal model of AH induced by norepinephrine. In the IPL model, whole lung filtration coefficient (K f ) was used as the index of lung permeability; pulmonary artery pressure (P pa ), pulmonary capillary pressures (P pc ), and zonal characteristics (ZC) were measured to assess the effects of ropivacaine on hemodynamics and their relationship to K f2 /K f1 . In vivo, ropivacaine effects were investigated on indices of pulmonary edema (changes in P a O 2 lung wet-to-dry ratio), changes in plasma volume and nitric oxide (NO) production. Key findings: Ropivacaine provided robust protection from pressure-dependent barrier failure; it inhibited pressure-induced increases in K f without affecting P pa , P pc or ZC. In vivo, ropivacaine prevented pressure-induced lung edema and associated hyperpermeability as evidence by maintaining P a O 2 , lung wet-to-dry ratio and plasma volume in levels similar to sham rats. Ropivacaine inhibited pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs. Significance: Collectively these data show that ropivacaine inhibits pressure-induced lung endothelial hyperpermeability and suggest that ropivacaine may be a clinically useful agent to prevent endothelial hyperpermeability when pulmonary pressure is acutely increased.",
keywords = "Local anesthetics, Mechanotransduction, Pulmonary edema and filtration coefficient, Vascular barrier",
author = "Milan Patel and Chignalia, {Andreia Z.} and Ayman Isbatan and Nikhil Bommakanti and Dull, {Randal O.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.lfs.2019.02.053",
language = "English (US)",
volume = "222",
pages = "22--28",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Ropivacaine inhibits pressure-induced lung endothelial hyperpermeability in models of acute hypertension

AU - Patel, Milan

AU - Chignalia, Andreia Z.

AU - Isbatan, Ayman

AU - Bommakanti, Nikhil

AU - Dull, Randal O.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Aims: Increases in hydrostatic pressure results in endothelial hyperpermeability via eNOS-dependent pathways. Ropivacaine is known to inhibit eNOS activation and to attenuate lung injury. Herein, we sought to determine if ropivacaine regulates pressure-induced lung endothelial hyperpermeability. Main methods: The effects of ropivacaine on lung permeability were assessed in two models of acute hypertension (AH): the isolated perfused lung preparation where acute increases in left atrial pressure model the hemodynamic changes of severe hypertension, and an animal model of AH induced by norepinephrine. In the IPL model, whole lung filtration coefficient (K f ) was used as the index of lung permeability; pulmonary artery pressure (P pa ), pulmonary capillary pressures (P pc ), and zonal characteristics (ZC) were measured to assess the effects of ropivacaine on hemodynamics and their relationship to K f2 /K f1 . In vivo, ropivacaine effects were investigated on indices of pulmonary edema (changes in P a O 2 lung wet-to-dry ratio), changes in plasma volume and nitric oxide (NO) production. Key findings: Ropivacaine provided robust protection from pressure-dependent barrier failure; it inhibited pressure-induced increases in K f without affecting P pa , P pc or ZC. In vivo, ropivacaine prevented pressure-induced lung edema and associated hyperpermeability as evidence by maintaining P a O 2 , lung wet-to-dry ratio and plasma volume in levels similar to sham rats. Ropivacaine inhibited pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs. Significance: Collectively these data show that ropivacaine inhibits pressure-induced lung endothelial hyperpermeability and suggest that ropivacaine may be a clinically useful agent to prevent endothelial hyperpermeability when pulmonary pressure is acutely increased.

AB - Aims: Increases in hydrostatic pressure results in endothelial hyperpermeability via eNOS-dependent pathways. Ropivacaine is known to inhibit eNOS activation and to attenuate lung injury. Herein, we sought to determine if ropivacaine regulates pressure-induced lung endothelial hyperpermeability. Main methods: The effects of ropivacaine on lung permeability were assessed in two models of acute hypertension (AH): the isolated perfused lung preparation where acute increases in left atrial pressure model the hemodynamic changes of severe hypertension, and an animal model of AH induced by norepinephrine. In the IPL model, whole lung filtration coefficient (K f ) was used as the index of lung permeability; pulmonary artery pressure (P pa ), pulmonary capillary pressures (P pc ), and zonal characteristics (ZC) were measured to assess the effects of ropivacaine on hemodynamics and their relationship to K f2 /K f1 . In vivo, ropivacaine effects were investigated on indices of pulmonary edema (changes in P a O 2 lung wet-to-dry ratio), changes in plasma volume and nitric oxide (NO) production. Key findings: Ropivacaine provided robust protection from pressure-dependent barrier failure; it inhibited pressure-induced increases in K f without affecting P pa , P pc or ZC. In vivo, ropivacaine prevented pressure-induced lung edema and associated hyperpermeability as evidence by maintaining P a O 2 , lung wet-to-dry ratio and plasma volume in levels similar to sham rats. Ropivacaine inhibited pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs. Significance: Collectively these data show that ropivacaine inhibits pressure-induced lung endothelial hyperpermeability and suggest that ropivacaine may be a clinically useful agent to prevent endothelial hyperpermeability when pulmonary pressure is acutely increased.

KW - Local anesthetics

KW - Mechanotransduction

KW - Pulmonary edema and filtration coefficient

KW - Vascular barrier

UR - http://www.scopus.com/inward/record.url?scp=85062283039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062283039&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2019.02.053

DO - 10.1016/j.lfs.2019.02.053

M3 - Article

C2 - 30822427

AN - SCOPUS:85062283039

VL - 222

SP - 22

EP - 28

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

ER -